Login
$OLMA
$7.36 -$0.20 (2.65%) Live

$OLMA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure +1 more

Section 1. Registered Office. The registered office of Olema Oncology, Inc. (the “Corporation”) in the State of Delaware shall as set forth in the certificate of incorporation of the Corporation, as the same may be amended or restated fr...

10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027

16 Oct 2026 SCHEDULE 13D/A
15 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective October 14, 2026. Dr. Hrustanovic also resigned fro...

02 Sep 2026 Form 4: O'Byrne Jason, CHIEF FINANCIAL OFFICER

Granted 650,000 Stock Option (Right to Buy)

13 Aug 2026 Form 3: O'Byrne Jason, CHIEF FINANCIAL OFFICER

No securities owned

13 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Olema Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment as its Chief Financial Officer, pursuant to the terms of this offer letter agreement (the “Agreement”).

10 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition

Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027

06 Aug 2026 SCHEDULE 13G/A
29 Jul 2026 SCHEDULE 13G/A
27 Jul 2026 Form 4: Harmon Cyrus, Director

Sold 12,500 shares ($145K) · Sold 12,500 shares ($146K)

24 Jul 2026 144
23 Jul 2026 144
23 Jun 2026 Form 4: Bvf Partners L P/IL, Director and 9 others

Granted 29,500 Stock Option (Right to buy)

23 Jun 2026 Form 4: Harmon Cyrus, Director

Granted 29,500 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Butitta Cynthia M, Director

Granted 29,500 Stock Option (right to buy)

23 Jun 2026 Form 4: Garland J. Scott, Director

Granted 29,500 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support